Beyond Chemoattraction: Multifunctionality of Chemokine Receptors in Leukocytes

Trends in Immunology

Volumn 38, Issue 12, 2017, Pages 927-941

  López Cotarelo, Pilar ^a   Gómez Moreira, Carolina ^a   Criado García, Olga ^a   Sánchez, Lucas ^a   Rodríguez Fernández, José Luis ^a  

^a CENTRO DE INVESTIGACIONES BIOLÓGICAS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR;

CYTOKINE RESPONSE; HOMEOSTASIS; HUMAN; IMMUNITY; INFLAMMATION; LEUKOCYTE; LEUKOCYTE FUNCTION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; CELL DIFFERENTIATION; CELL MOTION; CELL SURVIVAL; ENDOCYTOSIS; IMMUNOLOGY; METABOLISM; NEUTROPHIL CHEMOTAXIS;

ANIMALS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL SURVIVAL; CHEMOKINES; CHEMOTAXIS, LEUKOCYTE; ENDOCYTOSIS; HOMEOSTASIS; HUMANS; IMMUNITY; INFLAMMATION; LEUKOCYTES; RECEPTORS, CHEMOKINE;

EID: 85029535292     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2017.08.004     Document Type: Review

References (137)

1. Fernandez, E.J., Lolis, E., Structure, function, and inhibition of chemokines. Annu. Rev. Pharmacol. Toxicol. 42 (2002), 469–499.
2. Yoshimura, T., et al. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc. Natl. Acad. Sci. U. S. A. 84 (1987), 9233–9237.
3. Baggiolini, M., et al. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest. 84 (1989), 1045–1049.
4. Bachelerie, F., et al. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. 66 (2014), 1–79.
5. Zlotnik, A., Yoshie, O., The chemokine superfamily revisited. Immunity 36 (2012), 705–716.
6. Moser, B., et al. Chemokines: multiple levels of leukocyte migration control. Trends Immunol. 25 (2004), 75–84.
7. Wengner, A.M., et al. The coordinated action of G-CSF and ELR + CXC chemokines in neutrophil mobilization during acute inflammation. Blood 111 (2008), 42–49.
8. Kohler, A., et al. G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from bone marrow via induction of Cxcr2 ligands. Blood 117 (2011), 4349–4357.
9. Sanchez-Sanchez, N., et al. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J. Immunol. 176 (2006), 5153–5159.
10. Johnson, L.A., Jackson, D.G., Inflammation-induced secretion of CCL21 in lymphatic endothelium is a key regulator of integrin-mediated dendritic cell transmigration. Int. Immunol. 22 (2010), 839–849.
11. Grant, A.J., et al. Hepatic expression of secondary lymphoid chemokine (CCL21) promotes the development of portal-associated lymphoid tissue in chronic inflammatory liver disease. Am. J. Pathol. 160 (2002), 1445–1455.
12. Pease, J.E., Williams, T.J., Eotaxin and asthma. Curr. Opin. Pharmacol. 1 (2001), 248–253.
13. Matthews, A.N., et al. Eotaxin is required for the baseline level of tissue eosinophils. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 6273–6278.
14. White, G.E., et al. CC chemokine receptors and chronic inflammation–therapeutic opportunities and pharmacological challenges. Pharmacol. Rev. 65 (2013), 47–89.
15. Moser, B., Loetscher, P., Lymphocyte traffic control by chemokines. Nat. Immunol. 2 (2001), 123–128.
16. Vanbervliet, B., et al. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J. Exp. Med. 198 (2003), 823–830.
17. Umehara, H., et al. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler. Thromb. Vasc. Biol. 24 (2004), 34–40.
18. Williams, I.R., CCR6 and CCL20: partners in intestinal immunity and lymphorganogenesis. Ann. N. Y. Acad. Sci. 1072 (2006), 52–61.
19. Matloubian, M., et al. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat. Immunol. 1 (2000), 298–304.
20. + dendritic cells. J. Exp. Med. 207 (2010), 1283–1292.
21. + T cells. Immunity 31 (2009), 823–833.
22. Fox, J.C., et al. Structural and agonist properties of XCL2, the other member of the C-chemokine subfamily. Cytokine 71 (2015), 302–311.
23. Balabanian, K., et al. Role of the chemokine stromal cell-derived factor 1 in autoantibody production and nephritis in murine lupus. J. Immunol. 170 (2003), 3392–3400.
24. Rangel-Moreno, J., et al. Pulmonary expression of CXC chemokine ligand 13, CC chemokine ligand 19, and CC chemokine ligand 21 is essential for local immunity to influenza. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 10577–10582.
25. Svensson, M., Agace, W.W., Role of CCL25/CCR9 in immune homeostasis and disease. Expert Rev. Clin. Immunol. 2 (2006), 759–773.
26. Gombert, M., et al. CCL1–CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J. Immunol. 174 (2005), 5082–5091.
27. 2+]i changes and respiratory burst in human neutrophils and monocytes induced by NAP-1/interleukin-8, NAP-2, and gro/MGSA. J. Leukoc. Biol. 50 (1991), 279–286.
28. Walz, A., et al. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III and platelet factor 4 on human neutrophils. J. Exp. Med. 170 (1989), 1745–1750.
29. Walz, A., et al. Structure and neutrophil-activating properties of a novel inflammatory peptide (ENA-78) with homology to interleukin 8. J. Exp. Med. 174 (1991), 1355–1362.
30. Jin, L., et al. CXCL1 contributes to host defense in polymicrobial sepsis via modulating T cell and neutrophil functions. J. Immunol., 193, 2014 3549–3458.
31. Hazeldine, J., et al. Impaired neutrophil extracellular trap formation: a novel defect in the innate immune system of aged individuals. Aging Cell 13 (2014), 690–698.
32. Pang, L., et al. Pseudogout-associated inflammatory calcium pyrophosphate dihydrate microcrystals induce formation of neutrophil extracellular traps. J. Immunol. 190 (2013), 6488–6500.
33. Proost, P., et al. Human and bovine granulocyte chemotactic protein-2: complete amino acid sequence and functional characterization as chemokines. Biochemistry 32 (1993), 10170–10177.
34. Chabot, V., et al. CCL5-enhanced human immature dendritic cell migration through the basement membrane in vitro depends on matrix metalloproteinase-9. J. Leukoc. Biol. 79 (2006), 767–778.
35. Menten, P., et al. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev. 13 (2002), 455–481.
36. Locati, M., et al. Analysis of the gene expression profile activated by the CC chemokine ligand 5/RANTES and by lipopolysaccharide in human monocytes. J. Immunol. 168 (2002), 3557–3562.
37. Ness, T.L., et al. CCR4 is a key modulator of innate immune responses. J. Immunol. 177 (2006), 7531–7539.
38. Matsukawa, A., et al. Pivotal role of the CC chemokine, macrophage-derived chemokine, in the innate immune response. J. Immunol. 164 (2000), 5362–5368.
39. Ogilvie, P., et al. Eotaxin-3 is a natural antagonist for CCR2 and exerts a repulsive effect on human monocytes. Blood 102 (2003), 789–794.
40. Badewa, A.P., et al. Regulatory effects of eotaxin, eotaxin-2, and eotaxin-3 on eosinophil degranulation and superoxide anion generation. Exp. Biol. Med. 227 (2002), 645–651.
41. Robertson, M.J., Role of chemokines in the biology of natural killer cells. J. Leukoc. Biol. 71 (2002), 173–183.
42. Taub, D.D., et al. Alpha and beta chemokines induce NK cell migration and enhance NK-mediated cytolysis. J. Immunol. 155 (1995), 3877–3888.
43. Ley, K., Arrest chemokines. Microcirculation 10 (2003), 289–295.
44. Smith, D.F., et al. GRO family chemokines are specialized for monocyte arrest from flow. Am. J. Physiol. Heart Circ. Physiol. 289 (2005), H1976–H1984.
45. Nardelli, B., et al. Characterization of the signal transduction pathway activated in human monocytes and dendritic cells by MPIF-1, a specific ligand for CC chemokine receptor 1. J. Immunol. 162 (1999), 435–444.
46. Pallandre, J.R., et al. Dendritic cell and natural killer cell cross-talk: a pivotal role of CX3CL1 in NK cytoskeleton organization and activation. Blood 112 (2008), 4420–4424.
47. Lippert, U., et al. Expression and functional activity of the IL-8 receptor type CXCR1 and CXCR2 on human mast cells. J. Immunol. 161 (1998), 2600–2608.
48. Kanemitsu, N., et al. CXCL13 is an arrest chemokine for B cells in high endothelial venules. Blood 106 (2005), 2613–2618.
49. Campbell, J.J., et al. Chemokines and the arrest of lymphocytes rolling under flow conditions. Science 279 (1998), 381–384.
50. Constantin, G., et al. Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. Immunity 13 (2000), 759–769.
51. Islam, S.A., et al. Identification of human CCR8 as a CCL18 receptor. J. Exp. Med. 210 (2013), 1889–1898.
52. Torres Bacete, J., et al. The mammalian sterile20-like 1 (Mst1) kinase controls selective CCR7-dependent functions in human dendritic cells. J. Immunol. 195 (2015), 973–981.
53. Yanagawa, Y., Onoe, K., CCL19 induces rapid dendritic extension of murine dendritic cells. Blood 100 (2002), 1948–1956.
54. Yanagawa, Y., Onoe, K., CCR7 ligands induce rapid endocytosis in mature dendritic cells with concomitant up-regulation of Cdc42 and Rac activities. Blood 101 (2003), 4923–4929.
55. Riol-Blanco, L., et al. The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed. J. Immunol. 174 (2005), 4070–4080.
56. Mellado, M., et al. Chemokine signaling and functional responses: the role of receptor dimerization and TK pathway activation. Annu. Rev. Immunol. 19 (2001), 397–421.
57. Sanchez-Sanchez, N., et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood 104 (2004), 619–625.
58. Neptune, E.R., Bourne, H.R., Receptors induce chemotaxis by releasing the betagamma subunit of Gi, not by activating Gq or Gs. Proc. Natl. Acad. Sci. U. S. A. 94 (1997), 14489–14494.
59. Stein, J.V., et al. CCR7-mediated physiological lymphocyte homing involves activation of a tyrosine kinase pathway. Blood 101 (2003), 38–44.
60. o protein/PLC/PKCdelta/ERK leading to cell-cycle progression. Cytokine 50 (2010), 42–49.
61. Escribano, C., et al. CCR7-dependent stimulation of survival in dendritic cells involves inhibition of GSK3beta. J. Immunol. 183 (2009), 6282–6295.
62. Lopez-Cotarelo, P., et al. A novel MEK–ERK–AMPK signaling axis controls chemokine receptor CCR7-dependent survival in human mature dendritic cells. J. Biol. Chem. 290 (2015), 827–840.
63. Delgado-Martin, C., et al. Chemokine CXCL12 uses CXCR4 and a signaling core formed by bifunctional Akt, extracellular signal-regulated kinase (ERK)1/2, and mammalian target of rapamycin complex 1 (mTORC1) proteins to control chemotaxis and survival simultaneously in mature dendritic cells. J. Biol. Chem. 286 (2011), 37222–37236.
64. Wong, M.M., Fish, E.N., Chemokines: attractive mediators of the immune response. Semin. Immunol. 15 (2003), 5–14.
65. Yang, Y.M., et al. Beta-chemokine induction of activation protein-1 and cyclic AMP responsive element activation in human myeloid cells. Cell Growth Differ. 12 (2001), 211–221.
66. Zohar, Y., et al. CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis. J. Clin. Invest. 124 (2014), 2009–2022.
67. Sallusto, F., et al. The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18 (2000), 593–620.
68. Marsland, B.J., et al. CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity 22 (2005), 493–505.
69. Braun, A., et al. Afferent lymph-derived T cells and DCs use different chemokine receptor CCR7-dependent routes for entry into the lymph node and intranodal migration. Nat. Immunol. 12 (2011), 879–887.
70. Platt, C.D., et al. Mature dendritic cells use endocytic receptors to capture and present antigens. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 4287–4292.
71. Green, S.P., et al. Interleukin-8 (IL-8), melanoma growth-stimulatory activity, and neutrophil-activating peptide selectively mediate priming of the neutrophil NADPH oxidase through the type A or type B IL-8 receptor. J. Biol. Chem. 271 (1996), 25400–25405.
72. Gerszten, R.E., et al. MCP-1 and IL-8 trigger firm adhesion of monocytes to vascular endothelium under flow conditions. Nature 398 (1999), 718–723.
73. Khajoee, V., et al. Novel roles of osteopontin and CXC chemokine ligand 7 in the defence against mycobacterial infection. Clin. Exp. Immunol. 143 (2006), 260–268.
74. + T helper 1 cell differentiation. Immunity 37 (2012), 1091–1103.
75. Varona, R., et al. CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses. J. Clin. Invest. 107 (2001), R37–R45.
76. Forster, R., et al. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99 (1999), 23–33.
77. Forster, R., et al. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87 (1996), 1037–1047.
78. Nie, Y., et al. The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity. J. Exp. Med. 200 (2004), 1145–1156.
79. + dendritic cells and lymphotoxin-expressing B cells. Nat. Immunol. 13 (2012), 681–690.
80. Charo, I.F., Ransohoff, R.M., The many roles of chemokines and chemokine receptors in inflammation. N. Engl. J. Med. 354 (2006), 610–621.
81. Griffith, J.W., et al. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 32 (2014), 659–702.
82. Viola, A., Luster, A.D., Chemokines and their receptors: drug targets in immunity and inflammation. Annu. Rev. Pharmacol. Toxicol. 48 (2008), 171–197.
83. Olson, T.S., Ley, K., Chemokines and chemokine receptors in leukocyte trafficking. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283 (2002), R7–R28.
84. Molon, B., et al. T cell costimulation by chemokine receptors. Nat. Immunol. 6 (2005), 465–471.
85. Huttenlocher, A., Poznansky, M.C., Reverse leukocyte migration can be attractive or repulsive. Trends Cell Biol. 18 (2008), 298–306.
86. Poznansky, M.C., et al. Active movement of T cells away from a chemokine. Nat. Med. 6 (2000), 543–548.
87. Cascio, G., et al. CXCL12 Regulates through JAK1 and JAK2 Formation of Productive Immunological Synapses. J. Immunol. 194 (2015), 5509–5519.
88. Sanchez-Martin, L., et al. The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression. Blood 117 (2011), 88–97.
89. Kabashima, K., et al. CXCR4 engagement promotes dendritic cell survival and maturation. Biochem. Biophys. Res. Commun. 361 (2007), 1012–1016.
90. + T cells. J. Immunol. 167 (2001), 3064–3073.
91. Kaiser, A., et al. CC chemokine ligand 19 secreted by mature dendritic cells increases naive T cell scanning behavior and their response to rare cognate antigen. J. Immunol. 175 (2005), 2349–2356.
92. Schaerli, P., et al. Cutaneous CXCL14 targets blood precursors to epidermal niches for Langerhans cell differentiation. Immunity 23 (2005), 331–342.
93. Shurin, G.V., et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J. Immunol. 174 (2005), 5490–5498.
94. Bardi, G., et al. Rho kinase is required for CCR7-mediated polarization and chemotaxis of T lymphocytes. FEBS Lett. 542 (2003), 79–83.
95. + T cells. Cell Immunol. 231 (2004), 75–84.
96. + T lymphocytes from apoptosis. Clin. Cancer Res. 11 (2005), 7901–7910.
97. Morley, S.C., et al. The actin-bundling protein L-plastin dissociates CCR7 proximal signaling from CCR7-induced motility. J. Immunol. 184 (2010), 3628–3638.
98. Ploix, C., et al. A ligand for the chemokine receptor CCR7 can influence the homeostatic proliferation of CD4 T cells and progression of autoimmunity. J. Immunol. 167 (2001), 6724–6730.
99. Stein, J.V., et al. The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules. J. Exp. Med. 191 (2000), 61–76.
100. Zhou, S., et al. SLC/CCR7 stimulates the proliferation of BMDCs by the pNF-kappaB p65 pathway. Anat. Rec. 293 (2010), 48–54.
101. Link, A., et al. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat. Immunol. 8 (2007), 1255–1265.
102. Bardi, G., et al. The T cell chemokine receptor CCR7 is internalized on stimulation with ELC, but not with SLC. Eur. J. Immunol. 31 (2001), 3291–3297.
103. Ruckes, T., et al. Autocrine antiapoptotic stimulation of cultured adult T-cell leukemia cells by overexpression of the chemokine I-309. Blood 98 (2001), 1150–1159.
104. Youn, B.S., et al. Blocking of c-FLIP(L)-independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction. Blood 98 (2001), 925–933.
105. Tharp, W.G., et al. Neutrophil chemorepulsion in defined interleukin-8 gradients in vitro and in vivo. J. Leukoc. Biol. 79 (2006), 539–554.
106. Gibbons, D., et al. Interleukin-8 (CXCL8) production is a signatory T cell effector function of human newborn infants. Nat. Med. 20 (2014), 1206–1210.
107. Proost, P., et al. Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8. J. Immunol. 150 (1993), 1000–1010.
108. Kredel, S., et al. Phenotypic analysis of chemokine-driven actin reorganization in primary human neutrophils. Assay Drug Dev. Technol. 12 (2014), 120–128.
109. Rousselle, A., et al. CXCL5 limits macrophage foam cell formation in atherosclerosis. J. Clin. Invest. 123 (2013), 1343–1347.
110. Moser, B., et al. Neutrophil-activating properties of the melanoma growth-stimulatory activity. J. Exp. Med. 171 (1990), 1797–1802.
111. von Hundelshausen, P., et al. Platelet-derived chemokines in vascular biology. Thromb. Haemost. 97 (2007), 704–713.
112. Kohrgruber, N., et al. Plasmacytoid dendritic cell recruitment by immobilized CXCR3 ligands. J. Immunol. 173 (2004), 6592–6602.
113. Whiting, D., et al. Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production. J. Immunol. 172 (2004), 7417–7424.
114. + T cell subsets. J. Leukoc. Biol. 99 (2016), 857–862.
115. Shimaoka, T., et al. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J. Leukoc. Biol. 75 (2004), 267–274.
116. + NKT cells patrolling liver sinusoids. PLoS Biol., 3, 2005, e113.
117. Germanov, E., et al. Critical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells. J. Immunol. 181 (2008), 81–91.
118. Braun, M.C., et al. Selective suppression of IL-12 production by chemoattractants. J. Immunol. 164 (2000), 3009–3017.
119. Gu, L., et al. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404 (2000), 407–411.
120. Jiang, Y., et al. Monocyte chemoattractant protein-1 regulates adhesion molecule expression and cytokine production in human monocytes. J. Immunol. 148 (1992), 2423–2428.
121. Sierra-Filardi, E., et al. CCL2 shapes macrophage polarization by GM-CSF and M-CSF: identification of CCL2/CCR2-dependent gene expression profile. J. Immunol. 192 (2014), 3858–3867.
122. Diaz-Guerra, E., et al. CCL2 inhibits the apoptosis program induced by growth factor deprivation, rescuing functional T cells. J. Immunol. 179 (2007), 7352–7357.
123. Karpus, W.J., et al. Differential CC chemokine-induced enhancement of T helper cell cytokine production. J. Immunol. 158 (1997), 4129–4136.
124. Chensue, S.W., et al. Role of monocyte chemoattractant protein-1 (MCP-1) in Th1 (mycobacterial) and Th2 (schistosomal) antigen-induced granuloma formation: relationship to local inflammation, Th cell expression, and IL-12 production. J. Immunol. 157 (1996), 4602–4608.
125. + dendritic cells. Nat. Immunol. 1 (2000), 83–87.
126. Zou, W., et al. Macrophage-derived dendritic cells have strong Th1-polarizing potential mediated by beta-chemokines rather than IL-12. J. Immunol. 165 (2000), 4388–4396.
127. − dendritic cell maturation and activation following viral infection of the central nervous system: implications for a role in T cell activation. Virology 327 (2004), 8–15.
128. Kim, C.S., et al. Potential involvement of CCL23 in atherosclerotic lesion formation/progression by the enhancement of chemotaxis, adhesion molecule expression, and MMP-2 release from monocytes. Inflamm. Res. 60 (2011), 889–895.
129. Kim, J., et al. CK beta 8/CCL23 induces cell migration via the Gi/Go protein/PLC/PKC delta/NF-kappa B and is involved in inflammatory responses. Life Sci. 86 (2010), 300–308.
130. Cappello, P., et al. CC-chemokine ligand 16 induces a novel maturation program in human immature monocyte-derived dendritic cells. J. Immunol. 177 (2006), 6143–6151.
131. Elsner, J., et al. Human eotaxin represents a potent activator of the respiratory burst of human eosinophils. Eur. J. Immunol. 26 (1996), 1919–1925.
132. Dichmann, S., et al. Fractalkine induces chemotaxis and actin polymerization in human dendritic cells. Inflamm. Res. 50 (2001), 529–533.
133. Boehme, S.A., et al. The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J. Immunol. 165 (2000), 397–403.
134. Karlmark, K.R., et al. The fractalkine receptor CX3CR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology 52 (2010), 1769–1782.
135. Landsman, L., et al. CX3CR1 is required for monocyte homeostasis and atherogenesis by promoting cell survival. Blood 113 (2009), 963–972.
136. Limatola, C., Ransohoff, R.M., Modulating neurotoxicity through CX3CL1/CX3CR1 signaling. Front. Cell. Neurosci., 8, 2014, 229.
137. Byrnes, H.D., et al. Macrophage inflammatory protein-3 beta enhances IL-10 production by activated human peripheral blood monocytes and T cells. J. Immunol. 163 (1999), 4715–4720.